Pfizer begins testing its vaccine in young children

Pfizer has begun testing its COVID-19 vaccine in children younger than 12, a significant step in turning back the pandemic. The trial’s first participants, a pair of 9-year-old twin girls, were immunized at Duke University in North Carolina on Wednesday.اضافة اعلان

Results from the trial are expected in the second half of the year, and the company hopes to vaccinate younger children early next year, said Sharon Castillo, a spokeswoman for the pharmaceutical company.

Moderna also is beginning a trial of its vaccine in children 6 months to 12 years of age. Both companies have been testing their vaccines in children 12 and older, and expect those results in the next few weeks.

AstraZeneca last month began testing its vaccine in children six months and older, and Johnson & Johnson has said it plans to extend trials of its vaccine to young children after assessing its performance in older children.

Immunizing children will help schools to reopen as well as help to end the pandemic, said Dr. Emily Erbelding, an infectious diseases physician at the National Institutes of Health who oversees testing of COVID-19 vaccines in special populations.

An estimated 80 percent of the population may need to be vaccinated for the United States to reach herd immunity, the threshold at which the coronavirus runs out of people to infect. Some adults may refuse to be vaccinated, and others may not produce a robust immune response.

Children younger than 18 account for about 23 percent of the population in the United States, so even if a vast majority of adults opt for vaccines, “herd immunity might be hard to achieve without children being vaccinated,” Erbelding said.

Pfizer had initially said it would wait for data from older children before starting trials of its vaccine in children younger than 12. But “we were encouraged by the data from the 12 to 15 group,” said Castillo, who did not elaborate on the results so far.

Scientists will test three doses of the Pfizer vaccine — 10, 20 and 30 micrograms — in 144 children. Each dose will be assessed first in children 5-11, then in children 2-4, and finally in the youngest group, 6 months to 2 years.

After determining the most effective dose, the company will test the vaccine in 4,500 children. About two-thirds of the participants will be randomly selected to receive two doses 21 days apart; the remaining will get two placebo shots of saline. The researchers will assess the children’s immune response in blood drawn seven days after the second dose.


Children represent 13 percent of all reported cases in the United States. More than 3.3 million children have tested positive for the virus, at least 13,000 have been hospitalized and at least 260 have died, noted Dr. Yvonne Maldonado, who represents the American Academy of Pediatrics on the federal Advisory Committee on Immunization Practices.

The figures do not fully capture the damage to children’s health.

“We don’t know what the long-term effects of COVID infection are going to be,” Maldonado said.

Other vaccines have helped to control many horrific childhood diseases that can cause long-term complications, she added: “For some of us who’ve seen that, we don’t want to go back to those days.”

Children often react more strongly to vaccines than adults do, and infants and toddlers in particular can experience high fevers. Any side effects are likely to appear soon after the shot, within the first week and certainly within the first few weeks, experts have said.

Some vaccines are tested only in animals before being assessed in children and have to be monitored carefully for side effects.

“But this is a little different, because we’ve already had experience with tens of millions of people with these vaccines,” Maldonado said. “So there’s a higher degree of confidence now in giving this vaccine to kids.”

Some experts suggested that the Food and Drug Administration may require up to six months of safety data from studies of children before authorizing the COVID-19 vaccines. But a spokeswoman said the agency did not expect six months of safety data to support the vaccines’ authorization.

The Pfizer-BioNTech vaccine is authorized for children 16-18, and the authorization for that age group was based on just two months of safety data, she said.